Clinical trial
Vaccine Therapy in Treating Patients With Metastatic Melanoma
NCT00087373 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00087373 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Metastatic Melanoma |
| Official title | Phase II Study of Intratumoral Injection of rF-TRICOMTM in Patients With Metastatic Melanoma Who Have Detectable Tumor Associated T Cells |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Melanoma, Stage IV Melanoma |
| Intervention type | Biological, Other |
| Interventions | recombinant fowlpox-TRICOM vaccine, laboratory biomarker analysis |
| Enrollment | 28 |
| Start date | Jun 1, 2004 |
| Primary completion | Feb 1, 2006 |
| First posted | Jul 12, 2004 |
| Last update posted | Jun 9, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: